Axonics, Inc. - Common Stock (NQ:AXNX)

70.98 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axonics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year ↗

October 05, 2022

Biotech isn't the only place to make money in health care this year.

Via Investor's Business Daily

Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know ↗

October 05, 2022

Piper Sandler has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $82.00 to $84.00. Shares of Axonics are trading down 1.5% over the last 24 hours, at...

Via Benzinga

Where Axonics Stands With Analysts ↗

October 05, 2022

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

Via Benzinga

Is This Medical Gear Maker Ready To Continue Its Rally?

September 15, 2022

Medical gear maker Axonics rallied to a new high after an announcement that it entered the Canadian market. Is it set for bigger gains on strong revenue growth?

Via MarketBeat

Topics Intellectual Property

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

September 08, 2022

From Axonics, Inc.

Via Business Wire

What 9 Analyst Ratings Have To Say About Axonics ↗

August 02, 2022

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

Via Benzinga

Analyst Ratings for Axonics ↗

May 06, 2022

Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:

Via Benzinga

Axonics® to Participate in September Investor Conferences

August 18, 2022

From Axonics, Inc.

Via Business Wire

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

August 17, 2022

From Axonics, Inc.

Via Business Wire

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock

August 05, 2022

From Axonics, Inc.

Via Business Wire

Axonics® Announces Pricing of Public Offering of Common Stock

August 02, 2022

From Axonics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 02, 2022

Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...

Via Benzinga

Axonics® Announces Proposed Public Offering of Common Stock

August 02, 2022

From Axonics, Inc.

Via Business Wire

Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance ↗

August 02, 2022

Via Benzinga

Morgan Stanley Maintains Overweight Rating for Axonics: Here's What You Need To Know ↗

August 02, 2022

Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at...

Via Benzinga

Recap: Axonics Q2 Earnings ↗

August 01, 2022

Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by...

Via Benzinga

Axonics® Reports Second Quarter 2022 Financial Results

August 01, 2022

From Axonics, Inc.

Via Business Wire

Axonics® to Report Second Quarter 2022 Financial Results on August 1

July 11, 2022

From Axonics, Inc.

Via Business Wire

Earnings Scheduled For August 1, 2022 ↗

August 01, 2022

Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter.

Via Benzinga

Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

May 31, 2022

From Axonics, Inc.

Via Business Wire

Axonics® Reports First Quarter 2022 Financial Results

May 05, 2022

From Axonics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 05, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

April 26, 2022

From Axonics, Inc.

Via Business Wire

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

April 19, 2022

From Axonics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 18, 2022

Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.

Via Benzinga

Axonics® to Report First Quarter 2022 Financial Results on May 5

April 14, 2022

From Axonics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Axonics® Launches Direct to Consumer Television Advertising Campaign

April 04, 2022

From Axonics, Inc.

Via Business Wire

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout ↗

March 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...

Via Benzinga

FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System ↗

March 08, 2022

The FDA has approved Axonics Inc's (NASDAQ: AXNX) recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15 recharge-free...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.